Overexpression of HMGA1 proteins is a constant feature of human carcinomas. Moreover, rearrangements of this gene have been detected in several human benign tumors of mesenchymal origin. To define the role of these proteins in cell transformation in vivo, we have generated transgenic mice overexpressing ubiquitously the HMGA1 gene. These mice developed mixed growth hormone/prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas. The HMGA1-induced expression of IL-2 and IL-15 proteins and their receptors may account for the onset of these lymphomas. At odds with mice overexpressing a wild-type or a truncated HMGA2 protein, adrenal medullar hyperplasia and pancreatic islet cell hyperplasia frequently occurred and no increase in body size and weight was observed in HMGA1 mice. Taken together, these data indicate an oncogenic role of the HMGA1 gene also in vivo.
Introduction
HMGA1a and HMGA1b belong to the HMGA protein family, which includes the HMGA2 protein. They are encoded by the same gene, namely HMGA1, through alternative splicing (Johnson et al., 1989) . HMGA proteins bind to the minor groove of AT-rich DNA sequences, thereby inducing a bend within the DNA (Bustin and Reeves, 1996) . They are unable to stimulate initiation of transcription, but they can enhance promoter binding of transcription factors (Thanos and Maniatis, 1992) . HMGA gene expression is negligible in normal adult tissues, and is essentially restricted to embryonic development Chiappetta et al., 1996) . These data suggested that HMGA proteins play an important role in embryonic development. Indeed, impairment of the HMGA2 gene leads to pygmy mice, whereas transgenic mice carrying an activated form of the HMGA2 gene resulted in a giant phenotype (Battista et al., 1999; Arlotta et al., 2000) . This gene is also implicated in adipogenesis. In fact, targeting of the HMGA2 gene causes a drastic reduction in fat tissue, whereas its activation by the truncation of its carboxyterminal tail results in large accumulation of fat tissue in ectopic areas (Battista et al., 1999; Arlotta et al., 2000) . Moreover, disruption of the HMGA2 gene prevents both diet-and gene-induced obesity (Anand and Chada, 2000) . At odds with the HMGA2 gene, the HMGA1 gene seems to exert a negative effect on adipocytic cell growth control. In fact, suppression of HMGA1 protein synthesis in preadipocytic 3T3L1 cells stimulates proliferation and impairs adipocytic differentiation (Melillo et al., 2001) .
A body of evidence indicates that the HMGA genes play a critical role in the generation of benign and malignant tumors. In fact, HMGA2 and HMGA1 gene rearrangements have been found in human benign tumors of mesenchymal origin that carry a chromosomal translocation affecting regions 12q13-14 and 6p21, respectively Schoenmakers et al., 1995; Tkachenko et al., 1997; Xiao et al., 1997) . Moreover, HMGA gene overexpression is a feature of several human carcinomas (Tamimi et al., 1993; Chiappetta et al., 1995 Chiappetta et al., , 1998 Chiappetta et al., , 2001 Fedele et al., 1996; Bandiera et al., 1998; Abe et al., 1999 Abe et al., , 2000 , and appears causally associated with neoplastic transformation. In fact, HMGA1 protein blockage prevents thyroid cell transformation by the Kirsten murine sarcoma virus (Berlingieri et al., 2002) , and an adenovirus carrying the HMGA1 gene in an antisense orientation induced the death of thyroid anaplastic carcinoma cells (Scala et al., 2000) . In addition, HMGA1 overexpression induces the neoplastic phenotype in Rat1a cells (Wood et al., 2000) , and acquisition of the ability to form primary and metastatic tumors in nude mice by human breast epithelial cells (Reeves et al., 2001) .
Transgenic mice are a powerful experimental tool with which to examine the role of oncogenes in neoplastic processes in vivo (Hogan, 1983) . Consequently, to evaluate the oncogenic potential of HMGA1 overexpression in vivo, we generated transgenic mice carrying a wild-type (WT) HMGA1 gene under the transcriptional control of the cytomegalovirus (CMV) promoter, which is able to drive a high and essentially ubiquitous expression of the transgene (Battista et al., 1999) .
Here we show that transgenic mice carrying the HMGA1 WT gene developed mixed growth hormone/ prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas.
Results

Generation of transgenic mice overexpressing the HMGA1 gene
A WT HMGA1b cDNA under the transcriptional control of the CMV promoter ( Figure 1a ) was microinjected into B6C3F2 embryos and subsequently transferred to pseudopregnant females. Analysis of offspring by Southern blotting of the tail DNAs digested with SspI and hybridized with a cDNA corresponding to the CMV promoter revealed two potential founders (data not shown). They were bred with WT C57Bl6/J mice and two stable lines were obtained. Southern blot analysis confirmed the integration of the transgene (Figure 1b) . A similar number of integrated copies were found in both transgenic lines (data not shown). All founders transmitted the transgene in a Mendelian fashion (data not shown). Offspring that did not inherit the transgene were used as controls. Transgene expression was analysed by RT-PCR using total RNA extracted from muscle, lung, white adipose tissue (WAT), testis, heart, pituitary gland, liver, spleen, and kidney ( Figure 1c) . Transgene expression was similar in all the analysed tissues. Western blot analysis confirmed the expression of the HMGA1 protein in transgenic animal tissues (data not shown).
Stimulation of the IL-2 and IL-15 pathways causes HMGA1 transgenic mice to develop NK-T/NK cell lymphomas About 37% of HMGA1 mice killed at 18 months of age and 80% of those killed at 24 months of age, derived from the two founders, displayed a lymphoid pathology, very similar to that described in transgenic mice carrying a truncated HMGA2 gene (Baldassarre et al., 2001) . In fact, lymph nodes were about 2 cm in diameter and weighed almost 2 g; the spleen was between 2.0 and 4.0 cm long and weighed between 0.5 and 5 g (Figure 2 ). Tumors were detectable in the mesenteric lymph nodes, spleen, Peyer's plaques, and, in some instances, in the liver, thymus, and kidneys. These lymphomas contained large cells with histiocytic differentiation (data not shown). Immunohistochemical analysis showed that all lymphomas analysed were CD3 positive and CD20 negative (Figure 2, inset) .
FACScan analysis of lymphocytes isolated from pathological spleens using the CD3, B220, and CD19 anti-mouse antibodies revealed a predominantly 
Conversely, only 10% of cells were CD3 þ /B220 þ in splenocytes derived from WT animals ( Figure 3a) . As mice overexpressing the HMGA2 gene develop NK-T/NK cell lymphomas (Baldassarre et al., 2001; Fedele et al., 2002) , we analysed the lymphocytes from WT and pathological spleens for the expression of NK1.1, the typical NK-T cell surface antigen. As shown in Figure 3a , we observed a significant increase of NK1.1 þ cells compared to WT samples (30 vs 11%). A double-staining FACS analysis with CD3 and NK1.1 antibodies confirmed the NK-T nature of this population (Figure 3a) . We further demonstrated the co-localization of CD3 and B220 antigens through double immunofluorescence on lymphocytes derived from pathological spleens (Figure 3b) . Moreover, by this technique, we also showed the colocalization of the CD3 antigen and c-kit, a marker of NK cells in spleens (Figure 3b ), demonstrating once again the presence of NK-T cells in transgenic pathological spleens. On the basis of these results, we classified the neoplasias developed by transgenic mice overexpressing the HMGA1 gene as NK-T/NK cell lymphomas.
Previously, we demonstrated that stimulation of the pathway shared by IL-2 and IL-15 induced the development of lymphomas in HMGA2/T mice (Baldassarre et al., 2001) . Therefore, we analysed the expression of IL-2, IL-15, and their high-affinity receptors (IL-2R and IL-15R) in the lymphomatous tissues. As shown in Figure 4a , IL-2, IL-15, IL-2Ra, and IL-15R protein levels were significantly higher in the neoplastic tissues compared with normal spleen. The RT-PCR results showed that the upregulation of IL-2 and IL-15 occurred at mRNA level (data not shown), suggesting that transcriptional control plays a major role in the regulation of IL-2, IL-2 Ra, IL-15, and IL-15R gene expression induced by the HMGA1 transgene. We also analysed IL-15 and IL-15-Ra gene expression in spleens from young transgenic mice before the development of the malignancy. As shown in Figure 4b , we observed an increased expression of both IL-15 and IL-15-Ra (5-8-fold, as evaluated by densitometric analysis) even in these samples compared to WT controls, suggesting that the stimulation of the IL-15 pathway, induced by the HMGA1 overexpression, precedes the onset of the neoplastic phenotype. The HMGA1-mediated induction of IL-2 and IL-2Ra was expected from previous data (Himes et al., 1996) , and we previously found that HMGA1 proteins bind the IL-15 promoter (Baldassarre et al., 2001) . Here, we investigated the functional consequences of this binding on IL-15 promoter activity by transfecting the murine IL-15 promoter, cloned in a luciferase reporter vector (Azimi et al., 2000) with cDNAs expressing HMGA1 and NF-kB p65, into the DERL-7 NK-T leukemic cell line (Di Noto et al., 2001) . As shown in Figure 5 , the expression of NF-kB p65, consistently with previous results (Azimi et al., 2000) , enhanced the activity (4-5-fold) of the IL-15 promoter. Interestingly, HMGA1 cooperates with NF-kB p65, resulting in a further increase (10-fold) of the IL-15 promoter activity. More recent data from our laboratory demonstrate that NF-kB p65 and HMGA1 exert a strong synergistic effect also on the promoter 
HMGA1 mice develop pituitary adenomas
Most of the HMGA1 transgenic female mice, at about 14-16 months of age, showed head tilt. Autopsy of these mice revealed a large tumor at the base of the skull. This tumor was very similar to those described in HMGA2 transgenic mice : it was hemorrhagic, friable, and easily detachable from the surrounding brain tissue, without evidence of gross infiltration of the brain or sphenoid bone (Figure 6b and data not shown). Similarly, histological examination did not reveal any differences compared with the pituitary adenoma of HMGA2 transgenic mice that showed follicular type architecture with many blood lakes ( Figure 6c ). As already described for the HMGA2 transgenic mice, about 80% of the female HMGA1 transgenic mice had clearly evident pituitary adenomas by the age of 16 months. Pituitary adenomas appeared with a longer latency period (22 months of age) and a lower penetrance (about 15%) in male HMGA1 transgenic mice. Immunohistochemical analysis using antisera immunoreactive to murine pituitary hormones secreted from the anterior lobe was performed to define the subtype of the pituitary adenomas. As shown in Figure  6d and e, cytoplasmic immunoreactivity was intense for GH and PRL, whereas immunoreactivity was rare for melanocyte-stimulating hormone (MSH), adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), and follicle-stimulating hormone (FSH) (data not shown). Immunohistochemical studies with antisera immunoreactive to HMGA1 (Figure 6f ) showed strong, prevalently nuclear staining. Positive staining was also obtained with antisera immunoreactive to pit-1 (Figure 6g ), a gene encoding a transcriptional factor that has been shown to be critical for pituitary-specific activation of the GH and PRL genes. In situ double immunofluorescence showed that the tumors contained cells producing prolactin, cells producing growth hormone, and cells producing both hormones (data not shown). Therefore, the pituitary adenomas in HMGA1 mice, like those in HMGA2 mice, are constituted by three cell populations: GH-, PRL-, and GH/PRL-secreting populations. RT-PCR analysis confirmed a dramatic induction of GH and PRL gene expression in three representative HMGA1 pituitary adenomas (Figure 7 ).
HMGA1 mice showed adrenal medullar and islet pancreatic hyperplasias
A total of 25 HMGA1 mice were killed between the ages of 18 and 22 months and histologically analysed in toto. In addition to the lesions reported above and in Table 1 , lesions were found in the adrenal gland and pancreas. In the adrenal gland there were scattered and occasionally diffuse subcapsular aggregates of fusiform (type A) cells. In a few cases, they formed small nodules at the medullar/cortical interface (Figure 8a ). Adrenal medullary hyperplasia (Figure 8a ) was of the diffuse type with normal or slightly basophilic chromaffin cells, and occurred in 52% of animals. Most Langerhans islets of the pancreas were 2-3-fold larger than normal. Occasionally, they were seen as confluent masses and it was difficult to distinguish between islet cell hyperplasia and (Figure 8b-d) . Finally, mammary spindle cell sarcoma, lung adenoma, and endometrial hyperplasia were detected in a few cases (Figure 8e and data not shown).
Discussion
Protein HMGA1 is instrumental in the acquisition of the neoplastic phenotype (Berlingieri et al., 2002) and it has consistently been shown that HMGA1 exerts oncogenic activity in vitro (Wood et al., 2000) . We generated transgenic animals that overexpressed HMGA1 to determine whether the protein exerts oncogenic activity in vivo.
The HMGA1 transgenic mice developed two main neoplastic diseases. One appeared after about 12 months in females and after 16 months in males, and it consists of a pituitary adenoma that secreted PRL and GH. This tumor is indistinguishable from tumors previously described in HMGA2 transgenic mice . Our data show that the adenoma is not due to high expression of the transgene in the pituitary gland, but rather due to the role played by HMGA1 overexpression in regulating the growth of PRL-and GHsecreting cells. In fact, HMGA1 was expressed at a similar level in various tissues without inducing neoplasias other than the NK/T lymphoma. Moreover, the NK/T lymphoma is found also in transgenic animals carrying a truncated or WT HMGA2 gene (Baldassarre et al., 2001; Fedele et al., 2002) .
However, the HMGA1 gene does not seem to be involved in the generation of human pituitary adenomas. In fact, no alterations have been found in chromosome 6p21 (where the HMGA1 gene is located), and HMGA1 expression was unaltered in these human tumors (Finelli and Pierantoni, unpublished data) . Conversely, the HMGA2 locus is amplified in human prolactinomas, and is associated with HMGA2 overexpression (Finelli et al., 2002) .
The mechanisms governing the development of the pituitary neoplasms in HMGA1 transgenic mice are unknown; however, increased E2F activity related to HMGA1 binding to Rb proteins might be involved in this process. Experiments are in progress in our laboratory to verify this hypothesis by crossing the HMGA1 transgenic with E2F minus mice.
The NK-T/NK lymphomas that occur in HMGA1 transgenic mice are indistinguishable from those described in HMGA2/T transgenic mice (Baldassarre et al., 2001) . We hypothesize, as we did for the lymphomas of HMGA2/T mice, that the increased activity of IL-15 may be responsible for the NK-T/NK cell expansion, that in turn leads to the neoplastic phenotype. In fact, the enhancement of IL-15 and IL-15-Ra expression appears a quite early event in the process of lymphomagenesis, as demonstrated by its increased levels in the young spleens of the transgenic animals, likely as a direct effect of the HMGA1 expression. Our hypothesis is supported by the well-documented role of the IL-15 pathway in the NK-T lymphomas. In fact, transgenic mice overexpressing murine IL-15 showed an early expansion of NK and T lymphocytes and developed fatal T/NK lymphocytic leukemia (Fehniger et al., 2001) . Moreover, consistently with the critical role of the IL-15 pathway in the development of the lymphomas in HMGA1 and HMGA2 transgenic mice and with the finding that HMGA1 binds the IL-15 promoter region with lower avidity compared with HMGA2 (Baldassarre et al., 2001) , the transgenic mice overexpressing the HMGA1 gene developed lymphomas with a lower frequency and longer latency compared with mice carrying the HMGA2 gene.
Interestingly, the HMGA1 transgenic mice frequently developed islet pancreatic hyperplasia. This is consistent with the fact that HMGA1 is a positive regulator of the insulin receptor gene (Brunetti et al., 2001) . In fact, hyperexpression of the insulin receptor gene due to T/NK lymphomas and pituitary adenomas in HMGA1 transgenic mice M Fedele et al HMGA1 hyperexpression could enhance the insulin pathway, thereby causing hyperproliferation of the insulin producer islet pancreatic cells. Consistently, islets from HMGA1 null mice were 2-5-fold smaller compared with WT controls (manuscript submitted). At odds with the giant phenotype of the HMGA2 mice, which is accompanied by a dramatic increase in fat tissue (Battista et al., 1999) , there were no changes in body length or weight in our transgenic mice. This is consistent with our previous findings that HMGA1 overexpression blocked the growth of 3T3L1 cells and that inhibition of HMGA1 protein synthesis induced growth proliferation (Melillo et al., 2001) . Indeed, our data on 3T3L1 cells led us to expect a reduction in fat tissue. It is not unusual to find discrepancies between the regulation of pre-adipocytic cells in culture and adipocytic cell growth in vivo; one may envisage other mechanisms that could prevent the growth block exerted by HMGA1. Our result on unchanged body size would suggest that body length is controlled mainly by HMGA2 as opposed to HMGA1. However, it cannot be excluded that, even though HMGA1 might be involved in body size control, an increased expression does not allow a further increase being the physiological expression. This possibility is supported by a normal size of the HMGA1 knockout mice (Fedele et al., manuscript in preparation) .
It is intriguing that even though HMGA1 overexpression occurs in several human carcinomas (Chiappetta et al., 1995; Fedele et al., 1996; Abe et al., 1999; Baldassarre et al., 2003) and appears to be required for malignant transformation , no malignant tumors of epithelial origin developed in the HMGA1 transgenic mice. It is likely that HMGA1 overexpression is not able by itself to induce the malignant phenotype, and that other molecular events are required for this process. Therefore, we are now conducting experiments to investigate the ability of HMGA1 proteins to synergize with oncogenes in the process of neoplastic progression.
In conclusion, this study of the oncogenic effect of HMGA1 proteins on the pituitary cells that secrete GH and PRL and on NK/T cell lymphocytes suggests that the HMGA1 proteins play a critical role in controlling the growth of these cells.
Materials and methods
Generation of transgenic mice
The construct carrying the cDNA encoding the WT form of murine HMGA1b protein (pRc/CMV-HMGA1b) is described elsewhere (Melillo et al., 2001) . It was microinjected into fertilized eggs of B6C3F2 mice that were then transferred to the oviducts of pseudopregnant females (Laboratory Animal Facility, Thomas Jefferson University, Philadelphia, PA, USA). Two transgenic founder mice were obtained and crossed to C57 BL/6J WT mice to establish transgenic lines. Germline transmission of the transgene was checked by Southern blot analysis of tail DNA from F1 offspring using a CMV fragment as probe. The expression of the HMGA1b transgene was evaluated in various tissues by an RT-PCR assay using a construct-specific primer set, as described below.
RT-PCR analyses
Tissues from transgenic animals were rapidly dissected, frozen on dry ice and stored at À801C. Total RNA was extracted using TRI-reagent solution (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's protocol and treated with DNAase I (GenHunter Corporation, Nashville, TN, USA). In all, 1 mg of RNA was reverse transcribed using random exonucleotides as primers (100 mM) and MuLV reverse transcriptase (Perkin-Elmer). A volume of 5 ml of cDNA was amplified in a 25-l reaction mixture containing 1 U of Taq DNA polymerase (Boheringer), 0.4 mM dNTPs, 2.0 mM MgCl 2 , and 0.2 M of each primer. The PCR amplification was performed for 25 cycles (941C for 30 00 , 551C for 30 00 , and 721C for 30 00 ) using the Protocol Thermal Cycler (AMS Biotechnology). Primers designed to specifically amplify the transcripts of the transfected construct (forward primer: 5 0 -AGGAGAATGAGCGAGTCG-3 0 ; reverse primer: 5 0 -AGTCGAGGCTGATCAGCGAG-3 0 ) overlapped the 5 0 end of the cloned gene and the vector pRc/CMV downstream from the cloned gene, but upstream from the polyA signal site. Moreover, by using the same PCR conditions as above, we also used the following sets of primers to specifically amplify IL-15 and IL-15Ra gene transcripts: IL-15, forward primer ¼ 5 0 -CAGTTGCAGAGTTGGACG AA-3 0 ; IL-15, reverse primer ¼ 5 0 -ATGCCCAGGTAAGAGC TTCA-3 0 ; IL-15Ra, forward primer ¼ 5 0 -CTGACATCCGGG TCAAGAAT-3 0 ; IL-15Ra, reverse primer ¼ 5 0 -GCGGTATCT GATTTGGGAGA-3 0 . A set of primers specific for glyceraldehyde-phosphate-dehydrogenase (GAPDH) (forward: 5 0 -ACATGTTCCAATATGATTCC-3 0 and reverse: 5 0 -TGGA CTCCACGACGTACTCAG-3 0 ) or b-actin (forward: 5 0 -TCA GAAGGACTCCTATGTGG-3 0 and reverse: 5 0 -CGCAGCT CATTGTAGAAGGT-3 0 ) was added to each reaction to serve as internal control for the amount of cDNA tested. We also amplified RNA that was not reverse transcribed before PCR amplification (data not shown). The PCR products were separated on 2% agarose gel, blotted, and hybridized with specific probes.
Histological analysis
For light microscopy, tissues were fixed by immersion in 10% formalin and embedded in paraffin by standard procedures. Sections of 5 mm were stained with hematoxylin and eosin or hematoxylin and periodic acid/Schiff (PAS) reagent. Frozen sections, 4-8 mm thick, of WT and transgenic tissues were cut in a frozen microtome and allowed to dry for 1 h at room temperature, before fixing in acetone for 10 min. The slides were air dried for 2 h at room temperature and then placed in PBS for 5 min before the immunoperoxidase staining procedure.
Immunohistochemistry
Immunoperoxidase staining was carried out with the avidinbiotin-peroxidase LSAB þ kit (Dako) and microwave antigen retrieval. The antisera used were directed to HMGA1 (1 : 200; Chiappetta et al., 1995) , growth hormone (1 : 16 000) and prolactin (1 : 32 000). Growth hormone and prolactin antibodies were provided by Dr AF Parlow (National Hormone and Pituitary Program, Harbor-UCLA Medical Center, Torrance, CA, USA). For electron microscopy, tissues were processed by standard procedures as previously described (27).
Antibodies used in FACS analysis
The following monoclonal antibodies (mAbs) were used in this study: anti-mouse CD3e (FITC-conjugated, clone 145-2C11); anti-mouse B220 (PE-conjugated, clone RA3-6B2); anti-mouse CD19 (FITC-conjugated, clone ID3); anti-mouse c-Kit (PE-conjugated, clone 53-2.1); anti-mouse CD4 (PE-conjugated, clone RM4-5); anti-mouse CD8 (PE-conjugated, clone 53-6.7); anti-mouse CD25 (FITC-conjugated, clone PC61); anti-mouse CD44 (PE-conjugated, clone IM7); and anti-mouse NK1.1 (PE-conjugated, clone PK136). All mAbs were from PharMingen (San Diego, CA, USA).
Tissue sampling and flow cytometric analysis
Spleens, thymus, and lymph nodes from transgenic and WT mice were removed, pressed through a stainless steel mesh, and suspended in PBS. After one wash in PBS, the cells were resuspended in NH 4 Cl and washed twice more in PBS. Aliquots of lymphocytes (1x10 6 ) were placed in 96-well round-bottom plates, incubated for 30 min at room temperature with normal rat and goat IgG (Santa Cruz Inc.) and then for 1 h at 41C with the conjugated mAbs. The cells were washed twice in PBS and fixed in 1% paraformaldehyde, washed in PBS and analysed by flow cytometry (Coulter Count Becton Dickinson, San Jose, CA, USA) using CELLQuest TM software (Becton Dickinson). Viable lymphocytes were gated on the basis of forward and side scatter characteristics. A total of 10 000 gated events were analysed for each sample.
Immunoblot analysis of tissue samples
Total lysates were obtained from normal and neoplastic tissues that had been homogenized in a solution containing 10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, and 0.5 mM DTT. The tissue extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Immobilon-P transfer membranes (Millipore). Membranes were blocked with 5% nonfat milk proteins and incubated with antibodies at a dilution of 1 : 5000. Bound antibodies were detected by the appropriate horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (ECL; Amersham). To ascertain that equal loading of protein lysates, a parallel gel was loaded and stained with Ponceau Red. The same Western blots were incubated with antibodies against the b-actin protein.
Expression vectors
We used full-length HMGA1b cDNA cloned in the pRC-CMV vector as previously described , the IL-15 promoter (Azimi et al., 2000) cloned in the pGL-3 reporter vector (Promega), the p65 NF-kB subunit expression vector (Baldassarre et al., 2001) , and the pCMV-b-gal vector (Invitrogen).
Cell lines and transfections
DERL-7 cell line was grown in RPMI (GIBCO/BRL) supplemented with 20% FCS (GIBCO/BRL). The appropriate amount of cells (5 Â 10 6 /transfection) was starved 2 days before transfection with the pGL-3 construct with or without either NF-kB p65 or the HMGA1 expression vectors. The transfection was performed by using the Nucleofector Solution V (amaxa) and the Nucleofector device (amaxa) with electrical setting O-17, according to the manufacturer's instructions. Cells were harvested at 4 h post-transfection, and lysates were analysed for luciferase activity using the DUAL LIGHT kit (Tropix). Transfection efficiency was normalized according to galactosidase activity. All assays were performed in triplicate and repeated in three independent experiments.
